Browse > Article
http://dx.doi.org/10.7742/jksr.2015.9.6.393

A Study of Clinical Model for Radiation Therapy in Lung Cancer Patients of Busan and South Gyeongnam Province  

Son, Jongki (Dept. of Hospital Radiation Oncolog at Pusan National University)
Kim, Yunjin (Dept. of Family Medicin at Pusan National University)
Jo, Deokyoung (Dept. of Medical Business at Pusan National University)
Publication Information
Journal of the Korean Society of Radiology / v.9, no.6, 2015 , pp. 393-401 More about this Journal
Abstract
Radiation therapy for lung cancer is an effective treatment during monotherapy or combination therapy. Studies have reported that the optimum utilization rate of radiation therapy is estimated at 61% to 74%. Radiation therapy in Korea has been investigated to be low; further studies are needed. This study was intended to assess the appropriateness of the use of radiation and to reveal the use of radiation therapy-related factors by examining radiation therapy in lung cancer patients of Busan and South Gyeongnam Province. This study was aimed at the population diagnosed with lung cancer in Busan and South Gyeongnam Province. To conduct the study, 1036 patients enrolled in two hospitals were collected and 897 appropriate as subjects were selected. We compared the optimum utilization rate and actual rate of radiation therapy, and revealed the adequacy and related factors for use of radiotherapy. Of 897 patients, 503 (56%) were treated with medical therapy and 394 (44%) were given radiotherapy. The radiotherapy utilization rate of all lung cancer patients was 42%. The proportion of non-small cell lung cancer by histologic type was 33% and that of small cell lung cancer was 90%. Factors related to radiation therapy used in cancer were age, histological type, clinical stage, doctor refereed to, and clinical examination. Compared to radiation utilization by region (site), curative chest therapy was 42%; palliative treatment was 26%. In the comparison of histologic types, utilization of small-cell lung cancer is lower; the lowest especially in the stage III. Utilization of radiation therapy in Busan and South Gyeongnam Province was lower than the reasonable one. Utilization difference could be explained by patient factors, tumor factors, and health service factors. To improve utilization,development ofoutreach service programs and activation of the multidisciplinary team are required.
Keywords
lung cancer; radiation therapy; non-small cell lung cancer; small cell lung cancer; the optimal ratio; outreach services; multidisciplinary team;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Erridge SC, Thomson CS, Davidson J, "Scottish Cancer Trials Lung Group and The Scottish Cancer Therapy Network. Factors influencing the use of thoracic radiotherapy in lung cancer an analysis of the 1995 Scottish lung cancer audit", Clin Oncol (R Coll Radiol), 14, 219-227, 2002.   DOI   ScienceOn
2 Firat S, Byhardt RW, Gore E, "The effects of comorbidity and age on RTOG study enrollment in Stage III non-small cell lung cancer patients who are eligible for RTOG studies", Int J Radiat Oncol Biol Phys, 78, 1394-1399, 2010.   DOI   ScienceOn
3 "Annual report of cancer statistics in Korea in 2012", Ministry of Health and Welfare. Korea Central Cancer Registry, National Cancer Center, 2012.
4 Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, "Lung cancer In AJCC Cancer Staging Manual. 7th edition", Edited by American Joint Committee on Cancer (AJCC). New York: Springer-Verlag, 299-323, 2010.
5 Solda F, Lodge M, Ashley S, "Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; Systematic review and comparison with a surgical cohort", Radiotherapy and Oncology, 109:1-7, 2013.   DOI   ScienceOn
6 Langendijk JA, ten Velde GPM, Aaronson NK, "Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study", Int J Radiat OncolBiol Phys, 47, 149-155, 2000.   DOI   ScienceOn
7 Von Dincklage JJ, Ball D, Silvestri GA, "A review of clinical practice guidelines for lung cancer", J Thorac Disease,(suppl 5), 5, S607-S622, 2013.
8 Tyldesley S, Boyd C, Schulze K, "Estimating the need for radiotherapy for lung cancer: an evidence-based epidemiologic approach", Int J Radiat Oncol Biol Phys, 49, 973-985, 2001.   DOI   ScienceOn
9 The Cancer Council Australia, "Clinical Practice Guidelines for the Prevention, Diagnosis and Management of Lung Cancer. Canberra, New South Wales", Australia: National Health and Medical Research Council, 2004.
10 Ontario Cancer Treatment and Research Foundation, "A plan for radiation treatment, province of Ontario", 1995-2000.
11 Koning CC, Aarts MJ, Struikmans H, "Mapping use of radiotherapy for patients with non-small cell lung cancer in the Netherlands between 1997 and 2008", Clin Oncol (R Coll Radiol), 24, e46-e53, 2012.   DOI   ScienceOn
12 Delaney G, Barton M, Jacob S, "A model for decision making for the use of radio- therapy in lung cancer", Lancet Oncol, 4, 120-128, 2003   DOI   ScienceOn
13 Barbera L, Zhang-Salomons J, Huang J, Tyldesley S, Mackillop W, "Defining the need for radiotherapy for lung cancer in the general population: a criterion-based,benchmarking approach", Med Care, 41:1074-1085, 2003.   DOI   ScienceOn
14 Oken MM, Creech RH, Tormey DC, et al, "Toxicity and response criteria of the Eastern Cooperative Oncology Group", Am J Clin Oncol 5, 649-655, 1982   DOI
15 Shalini K. Vinod, MBBS, MD, FRANZCR, "Underutilization of Radiotherapy for Lung Cancer in New South Wales", Australia. Cancer, pp. 686-694. 2010.
16 london cancer alliance, "LCA Lung Cancer Clinical Guidelines December",[.nhs.uk], 2013
17 Clinical Guide line of the lung cancer,"Korean Association for the Study of Lung Cancer(2nd ed)", 2011.
18 Goffin J Lacchetti C, Ellis PM, Ung YC, "Evans WK: Fist-line chemotherapy in the treatment of advanced non-small cell lung cancer. A systematic review", J ThoracOncol, 5, 260-274, 2010.
19 Laroche C, Wells F, Coulden R. Improving surgical resection rate in lung cancer. Thorax, 53, 445-449, 1998.   DOI
20 Ball DL, Fisher R, Burmeister B, "Stage is not a reliable indicator of tumor volume in non-small cell lung cancer: a preliminary analysis of the Trans-Tasman Radiation Oncology Group 99-05 database", J Thorac Oncol1, 667-672, 2006.
21 Hayman JA, Abrahamse PH, Lakhani I, "Use of palliative radiotherapy among patients with metastatic non-small-cell lung cancer", Int J Radiat Oncol Biol Phys, 69, 1001-1007, 2007.   DOI   ScienceOn
22 Erridge SC, Thomson CS, Davidson J, "Scottish Cancer Trials Lung Group and The Scottish Cancer Therapy Network. Factors influencing the use of thoracic radiotherapy in lung cancer--an analysis of the 1995 Scottish lung cancer audit", Clin Oncol (R Coll Radiol), 14, 219-227, 2002.   DOI   ScienceOn
23 Stevens G, Stevens W, Purchuri S, "Radiotherapy utilization in lung cancer in New Zealand: disparities with optimal rates explained", NZ Med J, 122, 43-54, 2009.
24 Vinod SK, Barton MB, "Actual versus optimal utilization of radiotherapy in lung cancer: Where is the shortfall?", Asia-Pacific J Clin Oncol, 3, 1-7, 2007.   DOI   ScienceOn
25 Tyldesley S, Zhang-Salomons J, Groome PA, "Association between age and the utilization of radiotherapy in Ontario", Int J Radiat Oncol Biol Phys, 47, 469-480, 2000.   DOI   ScienceOn
26 Erridge SC, Murray B, Price A, "Improved treatment and survival for lung cancer patients in South-East Scotland", J Thorac Oncol, 3, 491-498, 2008.   DOI   ScienceOn
27 Laroche C, Wells F, Coulden R, "Improving surgical resection rate in lung cancer", Thorax, 53, 445-449, 1998.   DOI
28 Wassenaar TR, Eick hoff JC, Jarzemsky D, "Differences inprimary care clinicians' approach to non-small cell lung cancer patients compared with breast cancer", J Thorac Oncol, 2, 722-728, 2007.   DOI